Bloomberg -- Merck & Co. will start a new unit to copy biotechnology medicines, increasing the drugmaker’s stake in the $94 billion market for treatments based on living cells.
Bloomberg -- Merck & Co. will start a new unit to copy biotechnology medicines, increasing the drugmaker’s stake in the $94 billion market for treatments based on living cells.
